Key Trends and Insights into the Pediatric Growth Hormone Deficiency Market: Growth Rate and Opportunities to 2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the pediatric growth hormone deficiency market grown in recent years?
The market for pediatric growth hormone deficiency has expanded robustly in the past few years. It is projected to rise from $3.80 billion in 2024 to $4.16 billion in 2025, with a compound annual growth rate (CAGR) of 9.4%. The growth throughout the historical period is a result of heightened consciousness about treating pediatric growth disorders, enhanced diagnostic capabilities, increased research & development investment in next-gen products, and a solidified public insurance scheme.
How is the pediatric growth hormone deficiency market size expected to evolve during the forecast period?
In the coming years, the pediatric growth hormone deficiency market is predicted to experience significant expansion. The market size is forecasted to reach $5.88 billion by 2029, growing at a compound annual growth rate of 9.1%. Factors contributing to this growth for the forecast period include the enhancement of healthcare infrastructure, increased access to treatment, advancements in growth hormone therapies, increased awareness and advocacy for patients, government initiatives and policies related to healthcare and a rise in the occurrence of PGHD. Key trends forecasted for this period include, the creation of new therapies, options for personalized treatment, innovation in products, the use of telemedicine and remote surveillance, and individualized medicine coupled with genetic testing.
Get your pediatric growth hormone deficiency market report here!
Which key drivers are propelling the pediatric growth hormone deficiency market’s growth?
The expansion of the pediatric growth hormone deficiency market is anticipated to be driven by a growing prevalence of pediatric illnesses. These illnesses, typically affecting children from infancy through adolescence, are seeing a rise due to numerous factors: environmental influences, improved detection strategies, lifestyle shifts, genetic tendencies, and an increase in chronic conditions and allergies in children. These pediatric diseases can trigger pediatric growth hormone deficiency (GHD) by disturbing the hypothalamus or pituitary gland, the entities accountable for growth hormone generation. To elaborate, UNICEF, a US-based governmental body, reported in March 2024 that an estimated 4.9 million children under five years succumbed in 2022, with a daily average of 13,400 fatalities. On a global scale, infectious diseases such as pneumonia, diarrhea, and malaria, along with preterm birth and intrapartum-related complications, were key contributors to mortality rates in under-fives. Hence, the surging prevalence of pediatric diseases is fueling the expansion of the pediatric growth hormone deficiency market.
What are the market segments in the pediatric growth hormone deficiency industry?
The pediatric growth hormone deficiency market covered in this report is segmented –
1) By Type: Congenital GH Deficiency, Acquired GH Deficiency, Idiopathic GH deficiency
2) By Product: Recombinant Human Growth Hormone (rhGH), Human Growth Hormone (HGH) Analogs, Long-Acting Growth Hormones
3) By Route Of Administration: Subcutaneous, Intramuscular, Oral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Application: Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small For Gestational Age, Prader Willi Syndrome, Other Applications
Subsegments:
1) By Congenital GH Deficiency: Isolated GH Deficiency, Combined Pituitary Hormone Deficiency
2) By Acquired GH Deficiency: GH Deficiency Due To Pituitary Tumors, GH Deficiency Due To Brain Injury, GH Deficiency Due To Radiation Therapy
3) By Idiopathic GH Deficiency: Primary Idiopathic GH Deficiency, Secondary Idiopathic GH Deficiency
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21250&type=smp
Which leading companies are shaping the growth of the pediatric growth hormone deficiency market?
Major companies operating in the pediatric growth hormone deficiency market are Pfizer Inc., Eli Lilly and Company, Novo Nordisk A/S, Genentech Inc., Merck KGaA Darmstadt Germany, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., I-Mab Biopharma Co. Ltd., Ipsen Pharma, Gedeon Richter Plc, Ferring Pharmaceuticals, Celltrion Healthcare Co. Ltd., OPKO Health Inc., Zhejiang Hisun Pharmaceutical Co., Ltd., Dong-A ST Co. Ltd., Ascendis Pharma A/S, AnkeBio, Versartis Inc., Changchun Changsheng Life Sciences Ltd.
How are evolving market trends shaping pediatric growth hormone deficiency Strategies?
Primary corporations in the pediatric growth hormone deficiency market like Pfizer Inc. and OPKO Health Inc., are concentrating their efforts on creating novel solutions such as long-lasting, once-weekly human growth hormone (HGH) analogs. These are redesigned versions of the naturally occurring human growth hormone, they are designed to last longer in the body. For instance, in June 2023, these two US-based companies, Pfizer Inc, a pharmaceutical company, and OPKO Health Inc., a medication company, together announced the approval of NGENLA (somatrogon-ghla) by the Food and Drug Administration. This is a once-weekly human growth hormone analog specifically designed for the treatment of growth failure in pediatric patients aged three years and above due to limited secretion of the endogenous growth hormone. This groundbreaking treatment aims to enhance patient compliance by lessening the frequency of injections, unlike traditional treatments that typically necessitate daily doses. Clinical tests reveal that NGENLA has comparable effectiveness to daily growth hormone treatments, providing a more manageable and convenient alternative for children and their families.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21250
Which geographic areas are influencing the growth of the pediatric growth hormone deficiency market?
North America was the largest region in the pediatric growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric growth hormone deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Respiratory Disease Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report
Acute Respiratory Distress Syndrome Global Market Report 2025
Global Digital Diabetes Management Global Market Report 2025
https://thebusinessresearchcompany.com/report/digital-diabetes-management-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
